Who is sponsoring NCT02715258?

NCT02715258 is sponsored by Theracos.

What condition does NCT02715258 study?

NCT02715258 studies Type 2 Diabetes Mellitus.

What drugs are being tested in NCT02715258?

Interventions: Bexagliflozin, Placebo.

What is the status of NCT02715258?

NCT02715258 is currently COMPLETED.

Last reviewed 2021-06-02 · How we verify

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare the Efficacy and Safety of Bexagliflozin to Placebo in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

NCT02715258 Phase 3 COMPLETED Results posted

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).

Details

Lead sponsor	Theracos
Phase	Phase 3
Status	COMPLETED
Enrolment	210
Start date	2016-03
Completion	2017-04

Conditions

Type 2 Diabetes Mellitus

Interventions

Bexagliflozin
Placebo

Primary outcomes

Change in HbA1c From Baseline at Week 24 — 24 weeks
Glycated hemoglobin A1c (%) was measured using an HPLC method in the laboratories that had completed NGSP Level I laboratory certification and were traceable to the Diabetes Control and Complications Trial (DCCT) reference method.

Countries

United States, Canada